HHS Issues Enforcement Discretion Policy for Compounding with Certain Peptide Bulk Drug Substances Under 503A

What this means for your practice

This enforcement discretion policy provides crucial clarity and a temporary safe harbor for healthcare businesses involved in compounding, including many telehealth brands, medspas, and specialized clinics that utilize compounded medications. For practices offering treatments that incorporate peptide therapies, this policy significantly reduces the immediate federal regulatory risk associated with using specific peptide bulk drug substances that have not yet been formally added to the 503A bulks list. However, it is imperative for practices to understand that this is an *enforcement discretion*—not a final approval or a change in law—and it explicitly states it does not establish any rights and is not binding. Operators must remain vigilant for any safety signals or product quality issues that could lead HHS to revisit or revoke this interim policy. Additionally, adherence to all other state and federal compounding regulations, including patient-specific prescriptions and quality assurance, remains paramount. Practices should also contribute to the public comment process to help shape the final 503A bulks list.

The Department of Health and Human Services (HHS) has published a Notice in the Federal Register announcing the availability of an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." This significant development provides an interim regulatory framework for entities engaged in pharmaceutical compounding, particularly those utilizing specific peptide ingredients.

Understanding the Regulatory Landscape: Section 503A Compounding

Compounding is a long-standing practice in pharmacy where a licensed pharmacist, physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, prepares a customized medication for an individual patient. This customization can involve altering the form, dosage, or ingredients of a drug to meet unique patient needs that cannot be met by commercially available, FDA-approved products.

However, compounded drugs are generally not FDA-approved. This means that the FDA does not review their safety, effectiveness, or quality before they are marketed. While compounded drugs serve critical medical needs for certain patients—such as those with allergies to inactive ingredients in approved drugs or those requiring specific dosage strengths not commercially available—they can also pose unique risks if not prepared according to stringent standards.

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) outlines specific conditions under which pharmacies and physicians can compound drugs without being subject to new drug approval requirements. One of these conditions relates to the source of ingredients: drugs must be compounded using bulk drug substances that comply with a monographs of the USP-NF, have been made in an FDA-registered facility, or appear on a list of bulk drug substances for which there is a clinical need (the "503A bulks list"). The development of this 503A bulks list is a formal rulemaking process undertaken by the FDA, an agency within HHS.

The Challenge with Peptides and the Need for Discretion

Peptides are a class of compounds that are gaining increasing interest in various therapeutic applications. However, many peptide bulk drug substances are not yet formally included on the 503A bulks list, creating regulatory ambiguity for compounding pharmacies and physicians. The absence of these substances from the official list could potentially limit patient access to beneficial compounded peptide therapies.

HHS acknowledges this gap, stating, "Based on the Pharmacy Compounding Advisory Committee meetings and data regarding utilization of peptides, HHS believes that there is significant interest in the use of these peptides in compounding given the lack of availability of approved products." This recognition underscores a practical reality in healthcare where patient needs may outpace the formal regulatory listing processes.

Details of the Enforcement Discretion Policy

To address this challenge and ensure continued patient access, the Secretary of HHS is exercising enforcement discretion. This means that HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians who compound drug products using specific peptide bulk drug substances. These substances are identified in "Appendix A" of the full enforcement discretion policy document, which is available separately.

Crucially, this policy is an interim measure. It is designed to bridge the period during which the formal 503A bulks list is being developed through a comprehensive rulemaking process. The policy explicitly states that FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list, based on available evidence regarding their safety and clinical need.

Important Considerations and Limitations

Healthcare businesses must understand the nuances of an enforcement discretion policy:

• Interim Nature: This is not a permanent solution or a change in law. It is a temporary posture by HHS to allow continued access while a formal rulemaking proceeds.
• Conditional Application: The discretion applies to specific peptide bulk drug substances found in "Appendix A" of the policy. Practices must consult the official policy document to identify which peptides are covered.
• Revocable: HHS retains the right to "revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises with a compounded drug product within the scope of this policy." This highlights the ongoing responsibility of compounders to ensure the safety and quality of their preparations.
• No Rights Established: The draft Enforcement Discretion Policy "does not establish any rights for any person and is not binding on HHS or the public." This emphasizes its nature as a statement of current enforcement intent rather than a legally enforceable right for practitioners.
• Other Regulations Still Apply: This policy specifically addresses the use of certain bulk drug substances under 503A. All other applicable federal and state laws and regulations related to compounding, such as Good Manufacturing Practices (GMPs) where applicable, labeling, record-keeping, and requirements for patient-specific prescriptions, remain in full effect.

Opportunity for Public Comment

HHS has opened a period for public comment on this matter. Interested parties can submit written comments via regulations.gov on Docket No. HHS-OASH-2026-0496. The deadline for comments is two weeks after the publication date of October 30, 2026. This public comment period is a critical opportunity for compounding pharmacies, physicians, industry stakeholders, and patient advocacy groups to provide data and perspectives that can inform the final rulemaking process for the 503A bulks list.

Conclusion

The HHS Enforcement Discretion Policy for compounding with certain peptide bulk drug substances provides a necessary, albeit temporary, pathway for licensed practitioners to continue offering these therapies. While it offers regulatory relief, it also underscores the ongoing need for vigilance regarding product quality and safety, and adherence to all other applicable compounding regulations. Healthcare operators utilizing compounded peptides should review the full policy document, identify the specific peptides covered, and consider submitting comments to help shape the future regulatory landscape.

Key Facts

Frequently Asked Questions

What is this announcement from HHS about?

HHS is announcing the availability of an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." This document describes HHS's temporary enforcement policy for compounding with specific peptides while the official list of bulk drug substances under section 503A of the FD&C Act is being developed.

Why is HHS issuing this enforcement discretion policy?

HHS believes there is significant interest in using these peptides in compounding due to a lack of available FDA-approved products. The policy aims to expand and improve patient access during the period when the formal 503A bulks list is being created through rulemaking.

Who does this policy apply to?

HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A of the policy document.

Does this policy mean that compounded peptide drugs are now FDA-approved?

No, compounded drugs, including those made under this policy, are generally not FDA-approved. The FDA does not review their safety, effectiveness, or quality before they are marketed.

Is this enforcement discretion permanent?

No, this is an interim policy. HHS may revisit its application if, for instance, a safety signal or product quality issue arises with a compounded drug product. The policy also does not establish any rights for any person and is not binding on HHS or the public.

Source: HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · 2026-10-30